Use of protein repair therapy in the treatment of cystic fibrosis

Current Opinion in Pediatrics

Volumn 10, Issue 3, 1998, Pages 250-255

  Rubenstein, Ronald C ^a   Zeitlin, Pamela L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ARYLBUTYRIC ACID DERIVATIVE; GENTAMICIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CYSTIC FIBROSIS; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW;

CODON, TERMINATOR; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE EXPRESSION; GENTAMICINS; HUMANS; ION TRANSPORT; MEMBRANE PROTEINS; MOLECULAR CHAPERONES; MUTATION; PHENYLBUTYRATES;

EID: 0031710543     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199806000-00005     Document Type: Review

References (46)

1. Tsui LC: The cystic fibrosis conductance regulator gene. Am J Respir Crit Care Med 1995, 151 :S47-S53.
2. Frizzell RA: Functions of the cystic fibrosis conductance regulator protein. Am J Respir Crit Care Med 1995, 151:S54-S58.
3. MacLusky I, Levinson D: Cystic fibrosis. In Kendig's Disorders of the Respiratory Tract in Children, Edited by Chernig V, Kendig EL. Philadelphia: WB Saunders; 1990:692-730.
4. The Cystic Fibrosis Genetic Analysis Consortium, Edited by Tsui LC. Internet site www.genet.sickkids.on.ca/cftr/mutations.html; 1997. This site catalogs the known mutations and polymorphisms in the CFTR gene.
5. Welsh MJ, Smith AE: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993, 73:1251-1254.
6. Hamosh A, Trapnell BC, Zeitlin PL, Montrose-Rafizadeh C, Rosenstein BJ, Crystal RG, Cutting GR: Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J Clin Invest 1991, 88:1880-1885.
7. Hamosh A, Rosenstein BJ, Cutting GR: CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum Mol Genet 1992, 1:542-544.
8. Cystic Fibrosis Foundation: Patient Registry 1996 Annual Data Report. 1997 (Abstract).
9. Shoshani T, Augarten A, Gazit E, Bashan N, Yahav Y, Rivlin Y, Tal A, Seret H, Yaar L, Kerem E: Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet 1992, 50:222-228.
10. McCaughan KK, Brown CM, Dalphin ME, Berry MJ, Tate WP: Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc Natt Acad Sci U S A 1995, 92:5431-5435.
11. Martin R, Mogg AE, Heywood LA, Nischke L, Burke JF: Aminoglycoside suppression at UAG, UAA, and UGA codons in Escherichia coli and human tissue culture cells. Mol Gen Genet 1989, 217:411-418.
12. Howard M, Frizzell RA, Bedwell DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996, 2:467-469. These data demonstrate the suppression of nonsense mutations of the CFTR gene by aminoglycoside antibiotics in vitro. This paper is the basis for the ongoing clinical trial of gentamicin in patients with CF with nonsense CFTR mutations.
13. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ: Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1998, 3:1280-1284.
14. Ward CL, Kopito RR: Intracellular turnover of cystic fibrosis transmembrane conductance regulator: Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 1994, 269:25710-25718.
15. Pind S, Riordan JR, Williams DB: Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 1994, 269:12784-12788.
16. Yang Y, Janich S, Cohn JA, Wilson JM: The common variant of cystic fibrosis transmembrnae conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci U S A 1993, 90:9480-9484. These data demonstrate a potentially important protein-protein interaction of ΔF508-CFTR that may have a role in its aberrant intracellular trafficking and rapid intracellular degradation.
17. Bear CE, Li CH, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M, Riordan JR: Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992, 68:809-818.
18. Pasyk EA, Foskett JK: Mutant (delta F508) cystic fibrosis transmembrane conductance regulator Cl-channel is functional when retained in endoplasmic reticulum of mammalian cells. J Biol Chem 1995, 270:12347-12350. These data demonstrate that, although ΔF508-CFTR is targeted for rapid degradation in cells at physiologic temperature, it is still able to achieve an appropriate conformation for chloride transport.
19. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR: Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 1995, 83:129-135.
20. Ward CL, Omura S, Kopito RR: Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995, 83:121-127.
21. Bercovich B, Stancovski I, Mayer A, Blumenfeld N, Laszlo A, Schwartz AL, Ciechanover A: Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J Biol Chem 1997, 272:9002-9010. These data suggest that Hsc70, a member of the Hsp70 family, is important in targeting a number of cellular proteins for degradation by the ubiquitin-proteasome system. This may be important for CFTR trafficking, as ΔF508-CFTR is known to have a prolonged association with the Hsp70 family (see Yang et al. [16•]).
22. Denning GM, Anderson MA, Amara JF, Marshall J, Smith AE, Welsh MJ: Processing of mutant cystic fibrosis transmembrane regulator is temperature-sensitive. Nature 1992, 358:761-764. This paper demonstrates that ΔF508-CFTRs intracellular trafficking defect is reversible by reduced temperature.
23. Egan ME, Schwiebert EM, Guggino WB: Differential expression of ORCC and CFTR induced by low temperature in CF airway epithelial cells. Am J Physiol 1995, 268:C243-C251.
24. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ: Chemical chaperones correct the mutant phenotype of the deltaF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996, 1:117-125. This paper describes a class of protein-stabilizing compounds, the chemical chaperones, which promote correction of ΔF508-CFTRs intracellular processing defect.
25. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR: Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996, 271:635-638.
26. Qu BH, Strickland EH, Thomas PJ: Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding. J Biol Chem 1997, 272:15739-15744. These data present evidence that, in an in vitro protein folding system, the chemical chaperone glycerol can directly interact with, stabilize, and promote the folding of a peptide derived from ΔF508-CFTR.
27. Cheng SH, Fang SL, Zabner J, Marshall J, Piraino S, Schiavi SC, Jefferson DM, Welsh MJ, Smith AE: Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am J Physiol 1995, 268:L615-L624. This paper suggests that the transcriptional regulator butyrate promotes correction of the intracellular trafficking of ΔF508-CFTR.
28. Perrine SP, Ginder GD, Faller DV, Dover GJ, Ikuta T, Witkowski HE, Cai S-P, Vichinsky EP, Oliven NF: A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 1993, 328:81-86.
29. Rubenstein RC, Egan ME, Zeitlin PL: In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing deltaF508-CFTR. J Clin Invest 1997, 100:2457-2465. These data suggest that an analogue of butyrate that is approved for pharmaceutical use is able to promote ΔF508-CFTR trafficking to and functioning at the cell surface in vitro.
30. Rubenstein RC, Zeitlin PL: A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998, 157:484-490. This is the first published clinical trial of a protein repair agent. These data demonstrate small but statistically significant improvement on a physiologic measure of epithelial CFTR function in ΔF508-homozygous patients with CF.
31. Amemiya H: 15-Deoxyspergualin: A newly developed immunosuppressive agent and its mechanism of action and clinical effect: A review. Japan Collaborative Transplant Study Group for NKT-01. Artif Organs 1996, 20:832-835.
32. Nadeau K, Nadler SG, Saulnier M, Tapper MA, Walsh CT: Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry 1994, 33:2561-2567.
33. Nadler SG, Tepper MA, Schacter B, Mazzucco CE: Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 1992, 258:484-486.
34. Fang SL, O'Connor SP, Nadler SG, Lee DW, Jefferson DM, Kaplan JM, Smith AE, Jiang C, Cheng SH: Restoration of cAMP-stimulated chloride channel activity in deltaF508 cells by deoxyspergualin [abstract]. Pediatr Pulmonol Suppl 1997, 14:212.
35. Guay-Broder C, Jacobson KA, Barnoy S, Cabantchik ZI, Guggino WB, Zeitlin PL, Turner RJ, Vergara L, Eidelman O, Pollard HB: A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry 1995, 34:9079-9087. These data describe the in vitro effects of CPX, which is currently in a Phase I clinical trial in ΔF508-homozygous patients with CF.
36. Sheppard DN, Ostedgaard LS, Winter MC, Welsh MJ: Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. EMBO J 1995, 14:876-883.
37. Logan J, Hiestand D, Daram P, Huang Z, Muccio DD, Hartman J, Haley B, Cook WJ, Sorscher EJ: Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. J Clin Invest 1994, 94:228-236.
38. - channels with altered pore properties. Nature 1993, 362:160-164.
39. Hwang TC, Wang F, Yang IC, Reenstra WW: Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 1997, 273:C988-998. This paper describes the potentiation of CFTR channel activity by genistein, and suggests that genistein may be a useful protein repair agent.
40. Kelley TJ, Al-Nakkash L, Cotton CU, Drumm ML: Activation of endogenous (delta)F508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J Clin Invest 1996, 98:513-520.
41. Kelly TJ, Thomas K, Hilgram UH, Drumm ML: In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium. Proc Natl Acad Sci U S A 1997, 94:2604-2608. This report suggests the efficacy of milrinone, an approved pharmaceutical, in repairing CFTR function in a ΔF508-homozygous transgenic mouse model.
42. Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A, Gorvoy JD, Quittel L, Friedman KJ, Silverman LM: A novel mutation in the cystic fibrosis gene In patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994, 331:974-980.
43. Jacobson KA, Guay-Broder C, Van Galen PJ, Gallo-Rodriguez C, Melman N, Jacobson MA, Eidelman O, Pollard HB: Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve A1 adenosine receptors. Biochemistry 1995, 34:9088-9094.
44. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, Romey MC, Ruiz-Romero J, Verlingue C, Claustres M: Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995, 332:1475-1480.
45. Kiesewetter S, Macek M Jr, Davis C, Curristin SM, Chu CS, Graham C, Shrimpton AE, Cashman SM, Tsui LC, Mickle J, Amos J, Highsmith WE, Shuber A, Witt DR, Crystal RG, Cutting GR: A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 1993, 5:274-278. These data suggest that the expression of a mutant phenotype in patients with CF can depend on polymorphic, nonmutated regions elsewhere in the CFTR gene.
46. Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M, Yahav Y, Goshen R, Bentur L, Rivlin J, Aviram M, Genem A, Chiba-Falek O, Kraemer MR, Simon A, Branski D, Kerem B: A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med 1997, 155:1914-1920.